Navigation Links
Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity

CARLSBAD, Calif., Aug. 17 /PRNewswire/ -- AutoGenomics, a leader in developing automated molecular testing solutions, announced today that its CYP450 2C9-VKORC1 panel that it submitted to the FDA for 510(k) clearance late last year, has now been evaluated by the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG).

Warfarin (also called Coumadin) is a drug prescribed to help prevent blood clots. With more than 2 million prescriptions per year, one of the side effects of the drug is an increased risk of bleeding. The FDA re-labeled yesterday the warfarin package insert recommending the testing of multiple genetic variants in two genes namely 2C9 and VKORC1 for safer drug dosing.

"We have completed a successful evaluation of the INFINITI 2C9-VKORC1 panel which has the potential to optimize warfarin dosing and lower the risk of bleeding complications" said Dr. Raju Kucherlapati, Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) in Cambridge, Massachusetts. HPCGG is coordinating the "CReating an Optimal Warfarin Nomogram" (CROWN) Trial which is a prospective dosing study utilizing genetic testing to determine the optimal warfarin dose and how this information can be used for clinical care.

"We are pleased to see that through the re-labeling of the warfarin package insert, the FDA has recognized that patients with certain genetic variants may benefit from lower initial dosage thus reducing the risk of major bleeding events" said Ram Vairavan, Senior Vice President at AutoGenomics. He further said "Our expanded panel of genetic variants mentioned in the package insert encompassing African, Asian and other ethnic groups enables same day dosing on our automated multiplexing platform."

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine.

SOURCE AutoGenomics Inc

Copyright©2007 PR Newswire.

Related medicine technology :

1. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
2. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
3. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
7. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
(Date:12/1/2015)... 1, 2015 --> ... van Leeuwenhoek Hospital (NKI-AVL), among the world,s largest ... Leksell Gamma Knife® Icon™, the company,s latest generation ... --> --> With the ... treatments, Leksell Gamma Knife Icon offers greatly enhanced ...
(Date:12/1/2015)... Dec. 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast ... --> ) has announced the addition ... - Forecast to 2020" report to their ... ) has announced the addition of the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Physicians’ Education Resource®, LLC ... today announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will be ... and treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with powerful ...
(Date:12/1/2015)... ... 2015 , ... Growth in medical payments per workers’ compensation claim in Louisiana ... and nonhospital care, according to a recent study by the Workers Compensation Research Institute ... found medical payments per claim with more than seven days of lost time continued ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... solutions for the care management and population health arenas, is pleased to announce ... and cost containment services, has successfully implemented the ACUITY Complete Care™ Management to ...
Breaking Medicine News(10 mins):